The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
Dendritic cells (DCs) prime anti-tumor T cell responses in tumor-draining lymph nodes and can restimulate T effector responses in the tumor site. Thus, in addition to unleashing T cell effector activity, current immunotherapies should be directed to boost DC function. Herein, we review the potential...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/7/1525 |
| _version_ | 1797539934826921984 |
|---|---|
| author | Francisco J. Cueto David Sancho |
| author_facet | Francisco J. Cueto David Sancho |
| author_sort | Francisco J. Cueto |
| collection | DOAJ |
| description | Dendritic cells (DCs) prime anti-tumor T cell responses in tumor-draining lymph nodes and can restimulate T effector responses in the tumor site. Thus, in addition to unleashing T cell effector activity, current immunotherapies should be directed to boost DC function. Herein, we review the potential function of Flt3L as a tool for cancer immunotherapy. Flt3L is a growth factor that acts in Flt3-expressing multipotent progenitors and common lymphoid progenitors. Despite the broad expression of Flt3 in the hematopoietic progenitors, the main effect of the Flt3/Flt3L axis, revealed by the characterization of mice deficient in these genes, is the generation of conventional DCs (cDCs) and plasmacytoid DCs (pDCs). However, Flt3 signaling through PI3K and mTOR may also affect the function of mature DCs. We recapitulate the use of Flt3L in preclinical studies either as a single agent or in combination with other cancer therapies. We also analyze the use of Flt3L in clinical trials. The strong correlation between type 1 cDC (cDC1) infiltration of human cancers with overall survival in many cancer types suggests the potential use of Flt3L to boost expansion of this DC subset. However, this may need the combination of Flt3L with other immunomodulatory agents to boost cancer immunotherapy. |
| first_indexed | 2024-03-10T12:52:53Z |
| format | Article |
| id | doaj.art-0c2f90895fe442e2a7a34d2827e799f8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T12:52:53Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-0c2f90895fe442e2a7a34d2827e799f82023-11-21T12:06:13ZengMDPI AGCancers2072-66942021-03-01137152510.3390/cancers13071525The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer ImmunotherapyFrancisco J. Cueto0David Sancho1Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, SpainCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, SpainDendritic cells (DCs) prime anti-tumor T cell responses in tumor-draining lymph nodes and can restimulate T effector responses in the tumor site. Thus, in addition to unleashing T cell effector activity, current immunotherapies should be directed to boost DC function. Herein, we review the potential function of Flt3L as a tool for cancer immunotherapy. Flt3L is a growth factor that acts in Flt3-expressing multipotent progenitors and common lymphoid progenitors. Despite the broad expression of Flt3 in the hematopoietic progenitors, the main effect of the Flt3/Flt3L axis, revealed by the characterization of mice deficient in these genes, is the generation of conventional DCs (cDCs) and plasmacytoid DCs (pDCs). However, Flt3 signaling through PI3K and mTOR may also affect the function of mature DCs. We recapitulate the use of Flt3L in preclinical studies either as a single agent or in combination with other cancer therapies. We also analyze the use of Flt3L in clinical trials. The strong correlation between type 1 cDC (cDC1) infiltration of human cancers with overall survival in many cancer types suggests the potential use of Flt3L to boost expansion of this DC subset. However, this may need the combination of Flt3L with other immunomodulatory agents to boost cancer immunotherapy.https://www.mdpi.com/2072-6694/13/7/1525Flt3Flt3Ldendritic cellscancer immunotherapy |
| spellingShingle | Francisco J. Cueto David Sancho The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy Cancers Flt3 Flt3L dendritic cells cancer immunotherapy |
| title | The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy |
| title_full | The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy |
| title_fullStr | The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy |
| title_full_unstemmed | The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy |
| title_short | The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy |
| title_sort | flt3l flt3 axis in dendritic cell biology and cancer immunotherapy |
| topic | Flt3 Flt3L dendritic cells cancer immunotherapy |
| url | https://www.mdpi.com/2072-6694/13/7/1525 |
| work_keys_str_mv | AT franciscojcueto theflt3lflt3axisindendriticcellbiologyandcancerimmunotherapy AT davidsancho theflt3lflt3axisindendriticcellbiologyandcancerimmunotherapy AT franciscojcueto flt3lflt3axisindendriticcellbiologyandcancerimmunotherapy AT davidsancho flt3lflt3axisindendriticcellbiologyandcancerimmunotherapy |